A vaccine that could work against any coronavirus, known or unknown
Em maio de 2021, pesquisadores das universidades Duke e Carolina do Norte revelaram uma vacina capaz de proteger contra toda a família dos coronavírus, não apenas contra uma cepa isolada. A descoberta repousa sobre uma verdade elegante inscrita na arquitetura viral: uma região do espinho proteico permanece inalterada em todas as variantes e espécies conhecidas, tornando-se um alvo imunológico universal. Em um momento em que a humanidade aprendia, pela terceira vez em duas décadas, o custo de ser surpreendida por um coronavírus zoonótico, esse trabalho sugere que talvez seja possível antecipar a próxima pandemia antes que ela comece.
- Variantes surgiam mais rápido do que as vacinas podiam ser reformuladas, expondo a fragilidade de uma estratégia que perseguia o vírus em vez de antecipá-lo.
- Cinco macacos vacinados com a nova fórmula produziram anticorpos muito superiores aos gerados pelas vacinas de mRNA e resistiram à infecção por múltiplas espécies de coronavírus — nenhum animal do grupo adoeceu.
- O segredo estava em mirar o domínio de ligação ao receptor, a região do espinho proteico que o vírus não pode mudar sem perder sua capacidade de invadir células humanas.
- A proteção contra a variante sul-africana — projetada pela evolução para escapar de anticorpos — foi mais fraca, sinalizando que desafios ainda existem antes de uma aplicação clínica ampla.
- Mais do que uma vacina contra a COVID-19, o que os pesquisadores vislumbram é uma ferramenta capaz de interromper o ciclo histórico de pandemias por coronavírus, tendo em mãos a resposta antes da próxima ameaça emergir.
Em maio de 2021, pesquisadores de Duke e da Universidade da Carolina do Norte publicaram na capa da revista Nature um trabalho que redefinia o horizonte da vacinologia: uma vacina projetada para combater não um vírus, mas uma família inteira deles. O momento era carregado de significado — o mundo assistia ao surgimento contínuo de variantes e começava a compreender que perseguir cada mutação seria uma corrida sem fim.
A chave da descoberta estava na arquitetura do próprio vírus. O coronavírus invade células humanas por meio de uma proteína chamada espinho, e dentro dela existe uma região — o domínio de ligação ao receptor — que permanece fundamentalmente igual em todas as variantes e espécies conhecidas, incluindo as que circulam em morcegos e outros animais. Treinar o sistema imunológico para reconhecer essa região invariável significaria criar uma proteção válida para qualquer coronavírus, presente ou futuro.
A vacina foi construída com fragmentos proteicos organizados em nanopartículas, acompanhados de um adjuvante químico para amplificar a resposta imune — uma abordagem próxima à tecnologia da Novavax, mas com um alvo inteiramente novo. Nos testes com macacos cynomolgus, os animais vacinados produziram anticorpos muito superiores aos gerados por vacinas de mRNA e neutralizaram não apenas o coronavírus original, mas também as variantes britânica e brasileira. Frente à variante sul-africana, a proteção existiu, porém foi mais modesta. Ao serem expostos a múltiplas espécies do vírus, todos os animais vacinados permaneceram saudáveis.
O peso desse resultado vai além do laboratório. Estudos evolutivos mostram que a transmissão de coronavírus de animais para humanos ocorreu pelo menos três vezes nos últimos vinte anos — com o SARS, o MERS e a COVID-19. Cada vez, o mundo foi pego desprevenido. Uma vacina universal não eliminaria esse risco, mas transformaria radicalmente a resposta: em vez de correr para desenvolver imunizantes após o surgimento de uma nova pandemia, a humanidade poderia ter a ferramenta pronta com antecedência. É essa possibilidade — encerrar não apenas esta pandemia, mas o ciclo delas — que os pesquisadores enxergam no horizonte de seu trabalho.
In May 2021, researchers at Duke University and the University of North Carolina announced they had engineered a vaccine unlike any before it—one designed not to fight a single virus, but an entire family of them. The work appeared on the cover of Nature, one of science's most selective journals, and it arrived at a moment when the world was learning an uncomfortable lesson: new variants of the coronavirus kept emerging faster than vaccines could be reformulated to chase them.
The scientists had identified something elegant hidden inside the virus's architecture. The coronavirus enters human cells through a protein called the spike, which works like a key fitting into a lock on the cell's surface. Within that spike lies a smaller region, the receptor-binding domain, where the virus actually grabs hold. The researchers discovered that despite all the mutations and variations that had spawned the British, South African, and Brazilian strains, this binding domain remained fundamentally the same across every known coronavirus species—including those that live in bats and other animals. If they could train the immune system to recognize that unchanging region, they might create protection that worked across the entire coronavirus family, present and future.
The vaccine itself was constructed from protein fragments assembled into nanoparticles, tiny vessels designed to ferry the spike protein into cells where the body's immune machinery could study it and learn to recognize the threat. The formula included an adjuvant, a chemical booster that amplifies the immune response. The approach borrowed from technology already being used by Novavax, another vaccine maker, though the universal target was entirely novel.
To test whether the idea actually worked, the team vaccinated five cynomolgus macaques—the species found across Southeast Asia—with the new pancoronavirus vaccine, while others received either a placebo or a vaccine mimicking the mRNA shots already in use against COVID-19. The results were striking. The vaccinated monkeys produced far more of the critical antibodies than those given the mRNA mimic, and crucially, these antibodies could neutralize not just the original coronavirus but also the British and Brazilian variants. Against the South African variant, which carried mutations specifically designed by evolution to evade antibodies, the protection was weaker but still present.
When the researchers then exposed all the vaccinated monkeys to actual coronavirus—multiple species of it—every single animal remained uninfected. The placebo group and the mRNA-vaccinated group did not fare as well. Barton Haynes, the study's lead author from Duke's Human Vaccine Institute, described the finding with the careful language of science: they had essentially manufactured multiple small copies of the coronavirus to trigger a broad immune response, and what emerged was protection not just against infection but against a cross-reactive defense that recognized different coronavirus spike proteins as the same enemy.
The timing of this work carried weight beyond the laboratory. Evolutionary studies had shown that coronavirus transmission from animals to humans had happened at least three times in the past two decades—SARS, MERS, and now COVID-19. Each time, the world had been caught unprepared. A vaccine that could work against any coronavirus, known or unknown, would not eliminate that risk, but it could transform the response. Instead of waiting for a new pandemic to emerge, then racing to develop and distribute a vaccine, the world could have a tool already in hand. Haynes and his colleagues saw in their work the possibility of ending not just this pandemic, but the cycle of pandemics themselves—or at least, of being ready when the next one arrives.
Notable Quotes
We essentially manufactured multiple small copies of the coronavirus to trigger a broad immune response, and what emerged was protection not just against infection but against a cross-reactive defense that recognized different coronavirus spike proteins as the same enemy.— Barton Haynes, lead researcher, Duke University's Human Vaccine Institute
We've had three pandemics of Sars-related viruses in the last 20 years, so there is a need to develop effective vaccines that can bind to these pathogens before the next pandemic.— Barton Haynes
The Hearth Conversation Another angle on the story
So they found something the same in all these different coronaviruses? That seems almost too simple.
It is simple, which is partly why it's powerful. The spike protein mutates constantly—that's why we get variants. But the part where it actually grabs onto human cells, the receptor-binding domain, has to stay recognizable or the virus can't infect anything. It's a constraint built into the virus's own biology.
And they tested this on monkeys, not humans yet?
Five macaques, yes. They wanted to see if the immune system would actually produce the right antibodies, and whether those antibodies could stop infection. The monkeys vaccinated with this new vaccine did better than the ones given mRNA vaccines—more antibodies, and they worked against multiple variants.
But the South African variant still got through a little?
It did. That variant has mutations that specifically help it dodge antibodies. But even there, the protection held. The real test was when they exposed the vaccinated monkeys to actual virus. All of them stayed healthy. The placebo group didn't.
What makes this different from just updating the existing vaccines?
Existing vaccines are built to chase the virus as it changes. This one targets something the virus can't change without losing the ability to infect cells. It's like finding the one thing the virus absolutely needs and can't abandon.
And they're saying this could prevent the next pandemic?
That's the hope. Coronaviruses jump from animals to humans regularly. If we had a vaccine that worked against any coronavirus before the next jump happens, we'd be ahead of the virus for once instead of always behind it.